Identification of novel non-toxic and anti-angiogenic α-fluorinated chalcones as potent colchicine binding site inhibitors

被引:11
作者
Sun, Moran [1 ,2 ]
Yuan, Minghua [2 ]
Kang, Yingying [2 ]
Qin, Jinling [2 ]
Zhang, Yixin [2 ]
Duan, Yongtao [1 ]
Wang, Longfei [1 ]
Yao, Yongfang [1 ,2 ,3 ]
机构
[1] Zhengzhou Univ, Childrens Hosp, Henan Prov Key Lab Childrens Genet & Metab Dis, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Sch Pharmaceut Sci, Key Lab Adv Drug Preparat Technol, Minist Educ, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Sch Pharmaceut Sci, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Microtubules; zebrafish; angiogenesis; chalcone; fluorinated; VASCULAR DISRUPTING AGENTS; TUBULIN; CANCER; 2-METHOXYESTRADIOL; ANTITUMOR;
D O I
10.1080/14756366.2021.2014831
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
alpha-Fluorinated chalcones were prepared and evaluated for their cell growth inhibitory properties against six human cancer cell lines. The most potent chalcone 4c demonstrated excellent selective toxicity against cancer cells versus normal human cells, with IC50 values at nanomolar concentration ranges against 5 cancer cell lines. A further study revealed that 4c could bind to the colchicine site of tubulin, disrupt the cell microtubule networks, and effectively inhibit tubulin polymerisation. Cellular-based mechanism studies elucidated that 4c arrested MGC-803 cell cycle at G2/M phase. In addition, 4c dose-dependently caused Caspase-induced apoptosis of MGC-803 cells through mitochondrial dysfunction. Notably, compound 4c was found to inhibit the HUVECs tube formation, migration, and invasion in vitro. Furthermore, our data suggested that treatment with 4c significantly reduced MGC-803 cells metastasis and proliferation in vitro. Overall, this work showed that chalcone hybrid 4c is a potent inhibitor of tubulin assembly with prominent anti-angiogenesis and anti-cancer properties.
引用
收藏
页码:339 / 354
页数:16
相关论文
共 24 条
[1]   CELL CYCLE CONTROLS - POTENTIAL TARGETS FOR CHEMICAL CARCINOGENS [J].
AFSHARI, CA ;
BARRETT, JC .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1993, 101 :9-14
[2]   Antivascular and antitumor properties of the tubulin-binding chalcone TUB091 [J].
Canela, Maria-Dolores ;
Noppen, Sam ;
Bueno, Oskia ;
Prota, Andrea E. ;
Bargsten, Katja ;
Saez-Calvo, Gonzalo ;
Jimeno, Maria-Luisa ;
Benkheil, Mohammed ;
Ribatti, Domenico ;
Velazquez, Sonsoles ;
Camarasa, Maria-Jose ;
Fernando Diaz, J. ;
Steinmetz, Michel O. ;
Priego, Eva-Maria ;
Perez-Perez, Maria-Jesus ;
Liekens, Sandra .
ONCOTARGET, 2017, 8 (09) :14325-14342
[3]   ASSEMBLY OF PURIFIED GDP TUBULIN INTO MICROTUBULES INDUCED BY TAXOL AND TAXOTERE - REVERSIBILITY, LIGAND STOICHIOMETRY, AND COMPETITION [J].
DIAZ, JF ;
ANDREU, JM .
BIOCHEMISTRY, 1993, 32 (11) :2747-2755
[4]   Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity [J].
Ducki, Sylvie ;
Rennison, David ;
Woo, Meiko ;
Kendall, Alexander ;
Chabert, Jeremie Fournier Dit ;
McGown, Alan T. ;
Lawrence, Nicholas J. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (22) :7698-7710
[5]   Targeting caspases in cancer therapeutics [J].
Hensley, Patrick ;
Mishra, Murli ;
Kyprianou, Natasha .
BIOLOGICAL CHEMISTRY, 2013, 394 (07) :831-843
[6]   Cancer drug resistance: an evolving paradigm [J].
Holohan, Caitriona ;
Van Schaeybroeck, Sandra ;
Longley, Daniel B. ;
Johnston, Patrick G. .
NATURE REVIEWS CANCER, 2013, 13 (10) :714-726
[7]   Active cyclin B1-Cdk1 first appears on centrosomes in prophase [J].
Jackman, M ;
Lindon, C ;
Nigg, EA ;
Pines, J .
NATURE CELL BIOLOGY, 2003, 5 (02) :143-148
[8]   Targeted anti-mitotic therapies: can we improve on tubulin agents? [J].
Jackson, Jeffrey R. ;
Patrick, Denis R. ;
Dar, Mohammed M. ;
Huang, Pearl S. .
NATURE REVIEWS CANCER, 2007, 7 (02) :107-117
[9]   Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments [J].
Ji, Ya-Ting ;
Liu, Yan-Na ;
Liu, Zhao-Peng .
CURRENT MEDICINAL CHEMISTRY, 2015, 22 (11) :1348-1360
[10]   Integration of oncology and palliative care: a Lancet Oncology Commission [J].
Kaasa, Stein ;
Loge, Jon H. ;
Aapro, Matti ;
Albreht, Tit ;
Anderson, Rebecca ;
Bruera, Eduardo ;
Brunelli, Cinzia ;
Caraceni, Augusto ;
Cervantes, Andres ;
Currow, David C. ;
Deliens, Luc ;
Fallon, Marie ;
Gomez-Batiste, Xavier ;
Grotmol, Kjersti S. ;
Hannon, Breffni ;
Haugen, Dagny F. ;
Higginson, Irene J. ;
Hjermstad, Marianne J. ;
Hui, David ;
Jordan, Karin ;
Kurita, Geana P. ;
Larkin, Philip J. ;
Miccinesi, Guido ;
Nauck, Friedemann ;
Pribakovic, Rade ;
Rodin, Gary ;
Sjogren, Per ;
Stone, Patrick ;
Zimmermann, Camilla ;
Lundeby, Tonje .
LANCET ONCOLOGY, 2018, 19 (11) :E588-E653